The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE
OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8
COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP FIGI (to the nearest dollar) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
Adaptimmune Therapeutics plc Sponsored ADR 00653A107   4,405,481 5,555,461 SH   SOLE   5,555,461 0 0
Dyne Therapeutics, Inc. Common 26818M108   65,852,330 4,951,303 SH   SOLE   4,951,303 0 0
Entrada Therapeutics, Inc. Common 29384C108   66,785,081 4,425,784 SH   SOLE   4,425,784 0 0
Harpoon Therapeutics, Inc. Common 41358P205   3,560,356 313,136 SH   SOLE   313,136 0 0
iTeos Therapeutics, Inc. Common 46565G104   29,989,696 2,738,785 SH   SOLE   2,738,785 0 0
Repare Therapeutics, Inc. Common 760273102   16,371,243 2,242,636 SH   SOLE   2,242,636 0 0
Werewolf Therapeutics, Inc. Common 95075A107   16,536,904 4,284,172 SH   SOLE   4,284,172 0 0